



15 August 2025

Results of Extraordinary General Meeting

Melbourne, Australia, 15 August 2025: dorsaVi Limited (ASX: DVL) (**dorsaVi** or the **Company**) provides the following results of its extraordinary general meeting of shareholders in accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act.

All resolutions were passed on a poll. Details of resolutions, the proxies received, and the votes cast in respect of each resolution are set out in the attached results summary.

– ENDS –

For further information about dorsaVi, please contact:

Andrew Ronchi
Chief Executive Officer
+61 417 882 267
Email: ar@dorsavi.com

This announcement was authorised for release by the Board of dorsaVi.

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsavi.com

dorsaVi Ltd
2025 Extraordinary General Meeting
Friday, 15 August 2025 - Voting Results

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth)

Resolution Details			Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain	Carried/ Not Carried
1	Ratification of prior issue of Tranche 1 Placement Shares under Listing Rule 7.1	Ordinary	P	271,286,147 97.78%	436,272 0.16%	5,723,145 2.06%	112,057,692	277,024,444 99.84%	436,272 0.16%	500,000	Carried
2	Ratification of prior issue of Tranche 1 Placement Shares under Listing Rule 7.1A	Ordinary	P	268,337,942 97.58%	936,272 0.34%	5,723,145 2.08%	114,505,897	274,076,239 99.66%	936,272 0.34%	-	Carried
3	Approval to issue Tranche 2 Placement Shares	Ordinary	P	257,227,522 97.65%	471,272 0.18%	5,723,145 2.17%	126,081,317	262,965,819 99.82%	471,272 0.18%	500,000	Carried
4	Approval to issue Options to 62 Capital	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,229,539 99.67%	1,288,869 0.33%	-	Carried
5	Approval to issue Shares to Clayton Capital	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,229,539 99.67%	1,288,869 0.33%	-	Carried

6	Approval to issue Performance Rights to 62 Capital	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,214,387 99.67%	1,288,869 0.33%	-	Carried
7	Approval to issue Performance Rights to Mr Gernot Abl	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,229,539 99.67%	1,288,869 0.33%	-	Carried
8	Approval to issue Performance Rights to Mr Leigh Travers	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,229,539 99.67%	1,288,869 0.33%	-	Carried
9	Approval to issue Shares to Dr Andrew Ronchi	Ordinary	P	382,491,242 98.20%	1,288,869 0.33%	5,723,145 1.47%	-	388,229,539 99.67%	1,288,869 0.33%	-	Carried